ArticleStroke and vascular neurology2021
Incidence and prevalence of moyamoya disease in urban China: a nationwide retrospective cohort study.
Article in Stroke and vascular neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pooled it
- Sex differences in cardiovascular disease and dysregulation in Down syndrome.American journal of physiology. Heart and circulatory physiology · 2023Pooled it
- Benefits and risks of antiplatelet therapy for moyamoya disease: a systematic review and meta-analysis.Frontiers in neurology · 2023Pooled it
- Clinical features, treatment and long-term outcomes of hemorrhagic moyamoya disease in children: an extensive follow-up study.Stroke and vascular neurology · 2026Article
- RNF213 in Panvascular Disease: A Molecular Hub Linking Genetic Susceptibility to Systemic Vasculopathy.Biomedicines · 2026Review
- Spatiotemporal distribution and clinical manifestations of moyamoya disease in Jiangxi Province, China: a retrospective hospital-based study.BMJ public health · 2026Article
- Risk Factors Influencing Disease Onset and Surgical Outcomes in Moyamoya Disease.Journal of multidisciplinary healthcare · 2026Article
- Treatment Options for Patients With Moyamoya Disease: A Retrospective Cohort Study.Revista de neurologia · 2025Article
- The role of systemic inflammation in the formation and rupture of intracranial aneurysms in moyamoya disease: a retrospective cohort study.Annals of medicine · 2025Article
- MicroRNA-29b-3p promotes endothelial cell inflammation via NTRK2/PI3K/NLRP3 pathway in Moyamoya disease.European journal of medical research · 2025Article
- Psychological outcomes and health-related quality of life changes in Chinese patients with moyamoya disease after revascularization.Frontiers in surgery · 2025Article
- Coexistence of Hereditary Hemorrhagic Telangiectasia and Moyamoya Disease: A Case Report Highlighting a Potential Genetic Synergy.The application of clinical genetics · 2025Article
- Comparing Outcomes of Moyamoya Disease and Moyamoya Syndrome in a Real-World Scenario: A Cohort Study.CNS neuroscience & therapeutics · 2024Article
- GM-CSF Promotes the Development of Dysfunctional Vascular Networks in Moyamoya Disease.Neuroscience bulletin · 2024Article
- High lipoprotein(a) concentration is associated with moyamoya disease.Lipids in health and disease · 2024Article
- Superficial temporal artery-middle cerebral artery bypass in combination with encephalo-myo-synangiosis in Chinese adult patients with moyamoya disease.Frontiers in surgery · 2023Article
- Plasma exosomal microRNAs are non-invasive biomarkers of moyamoya disease: A pilot study.Clinics (Sao Paulo, Brazil) · 2023Article
- Parent artery occlusion for ruptured aneurysms in moyamoya vessels or on collaterals.Frontiers in neurology · 2023Article
- Article
- Endovascular treatment of main trunk aneurysms in the residual anterior circulation in moyamoya disease.The neuroradiology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveMoyamoya disease (MMD) is an increasingly recognised cause of stroke, mainly described in East Asia. China is the largest nation in Asia, but few studies reported the epidemiology of MMD, especially at a national level. We aimed to estimate the incidence and prevalence of MMD in China.
methodsWe performed a population-based study using data from the national databases of Urban Basic Medical Insurance between 2013 and 2016, covering approximately 0.50 billion individuals. MMD cases were identified by diagnostic code (International Classification of Diseases, 10th Revision I67.5) or related diagnostic text.
resultsA total of 1987 MMD patients (mean age 44.45±14.30 years, female-to-male ratio 1.12) were identified, representing a national crude incidence of 0.59 (95% CI: 0.49 to 0.68) and a prevalence of 1.01 (95% CI: 0.81 to 1.21) per 100 000 person-years in 2016. Rates were higher in females than in males for the incidence (0.66 vs 0.52) and prevalence (1.05 vs 0.90). And the age-specific rates showed a bimodal distribution, with the highest peak in middle-aged group and the second peak in child group.
conclusionsOur results confirm that MMD is relatively common in East Asians, but the rates in China were lower than those in other East Asian countries such as Japan and Korea. The unique epidemiological features, including a relatively weak female predominance and a shift in the highest peak of incidence from children to adults, revealed new sight into MMD. Further research is expected to explore the potential pathogenesis of MMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.